Amid proliferation of digital platforms for documentation and process execution, biopharma companies are exploring new ...
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining MER511, a Phase I therapy targeting ...
Large-scale validation of regenerative medicine, especially based on cell therapies, may come from cell therapies developed ...
Argentine biotech firm Biosidus tripled its cell culture capacity with a $12.9 million expansion to boost biosimilar ...
Bristol Myers Squibb subsidiary RayzeBio has committed to building a radiopharmaceutical manufacturing facility in Whitestown ...
Earlier this week, it was confirmed that a $380 million partnership between Bristol Myers Squibb (BMS) and contract ...
Industry expert Charley Maxwell shares essential strategies for biotech companies navigating Europe's fragmented regulatory ...
An expert from CTMC told BioProcess International how recent projects in Houston speak to the city’s drive to become a ...
Elizabeth Hunt ...
BPI Contributor Gearoid O’Rourke ...
Genentech will invest $750 million in a fill-finish facility in Oregon, reached a construction milestone in North Carolina, ...
Vendor governance in the biopharmaceutical industry is more than relationship management and periodic status review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results